Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
450 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04582955 | Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy | unknown | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04646824 | Almonertinib With Chemotherapy in mEGFR NSCLC | unknown | Phase 2 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 2, 2020 |
| NCT04631757 | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | unknown | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT03478449 | The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer | unknown | N/A | 276 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04530227 | Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04553887 | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial(AUTUMN) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04526028 | Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China | unknown | — | 612 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03983096 | Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. | completed | — | 1,213 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03987698 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03987867 | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04193098 | Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | unknown | Phase 1 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04079283 | Radiomics of Immunotherapeutics Response Evaluation and Prediction(RIREP) | completed | — | 285 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04218253 | Clinical Application of Nutrition Support Package Before Hepatectomy | unknown | N/A | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT03121833 | Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma | completed | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT03222440 | Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC | completed | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04171986 | Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis | unknown | N/A | 93 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04137679 | Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT04126811 | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT04126993 | Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma | unknown | Phase 2 | 80 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT04108494 | A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in Gastrectomy(TOP1) | unknown | N/A | 418 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT04029350 | Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M(ALTN-03) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063462 | Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03992833 | Methods of Computed Tomography Screening and Management of Lung Cancer | unknown | N/A | 4,000 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03992885 | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. | unknown | Phase 3 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03944980 | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer | unknown | Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03874000 | Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients(SMART) | unknown | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03837782 | Outcome of Resection for Colorectal Cancer(LRLCC) | enrolling by invitation | N/A | 1,300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03671265 | Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC | unknown | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03779035 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection(AdBTC-1) | unknown | Phase 3 | 460 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03745846 | A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization | unknown | Phase 2 | 78 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 19, 2018 | clinicaltrials |
| NCT03743324 | Effect of Radiation and Its Timing on Breast Reconstruction in Chinese Patients | unknown | — | 1,344 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03742908 | Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients | unknown | N/A | 291 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03708042 | A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer | unknown | Phase 3 | 220 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 16, 2018 | clinicaltrials |
| NCT03609918 | Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing | completed | — | 513 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 7, 2018 | clinicaltrials |
| NCT02948855 | Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases | withdrawn | — | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT02486198 | Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer | completed | Phase 3 | 145 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03398122 | Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma(HCC) | unknown | N/A | 248 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT03366883 | Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC | unknown | Phase 3 | 420 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT03389659 | XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC | unknown | Phase 3 | 750 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jan 3, 2018 | clinicaltrials |
| NCT03358602 | Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer | not yet recruiting | N/A | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT03367884 | Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal Cancer | not yet recruiting | N/A | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT03359694 | Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer | unknown | Phase 3 | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT03348098 | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT03355612 | XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma | unknown | Phase 3 | 456 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 28, 2017 | clinicaltrials |
| NCT03285906 | An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric | unknown | Phase 2 / Phase 3 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT03236883 | Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer(HST) | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT02959385 | A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 18, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials